Press Release January 2, 2006

Immunomic Therapeutics, Inc. Ph: 240-731-52329290 Gaither Road Fax: 240-597-4061Gaithersburg, MD 20877 info@immunomictherapeutics.com www.immunomix.com

FOR IMMEDIATE RELEASE: January 2, 2006 (Gaithersburg, MD)

Immunomic Therapeutics Begins Operations in Earnest; Looks Forward to2006

Gaithersburg, MD, January 2, 2006 /-- Immunomic Therapeutics, Inc. (ITI,www.immunomictherapeutics.com) announced today that it is officially startingoperations today and that it has appointed Dr. Bill Hearl, most recently the ChiefScientific Officer of Capital Genomix, to be the President and CEO of ITI.

ITI has been organized for the expressed purpose of commercializing LAMP basedvaccines as part of collaboration between Johns Hopkins University and CapitalGenomix, Inc., a Maryland based biotechnology company. “Over the first fewmonths of 2006 we will work with Johns Hopkins to work out terms of a licenseagreement. Once that work is complete we will begin looking to capture sub-licensees and collaborators to begin the commercialization process,” said Dr. Hearl.According to Hearl, the Company expects to have the license completed and the firstsub-license in place before the end of the year.

About Capital Genomix, Inc.

Capital Genomix, a biotechnology company located in Gaithersburg, Maryland, possesses two powerfuland proprietary genomic and proteomic drug development technology platforms. Capital Genomix intendsto couple these platforms – GeneSystem320™ (GS320™) for analytical study of genes and geneexpression and ImmunoMouse™ for the development of specific antibodies against genetic sequences ofbiological significance – into a unified, end-to-end gene discovery, functional analysis and target validationsystem. Capital Genomix intends to utilize these technologies to enable biopharmaceutical collaboratorsto go from gene study and discovery through function analysis and target validation and directly topotential therapeutic agents and diagnostic targets. For additional information visitwww.capitalgenomix.com.

About Immunomic Therapeutics

Immunomic Therapeutics, Inc. (“ITI”) is a privately held biotechnology company headquartered inGaithersburg, Maryland that is commercializing a portfolio of clinical applications based on “LAMP” vaccinetechnology. ITI offers access to LAMP – based vectors and novel vaccine design through license andcollaborative research agreements. More information about ITI and LAMP technology can be obtainedfrom www.immunomix.com or www.immunomictherapeutics.com .

This press release may contain forward looking statements regarding, among other matters, theCompany's future prospects. Forward looking statements address matters that are subject to a number ofrisks and uncertainties that can cause actual results to differ materially. Investors are cautioned that suchforward-looking statements in this press release regarding potential applications of ITI’s technologies,constitute forward-looking statements that involve risks and uncertainties, including, without limitation,risks inherent in the development and commercialization of potential products, uncertainty of clinical trialresults or regulatory approvals or clearances, need for future capital, dependence upon collaborators andmaintenance of our intellectual property rights. Future results of the Company will depend on a variety offactors, including the timing of significant orders, the ability of the Company to timely manufacture anddeliver ordered products, the ability of the Company to bring new systems to market, the timing of newproduct releases by the Company's competitors and other competitive factors.

Press Release January 2, 2006

____________________________CONTACT:Immunomic Therapeutics, Inc.Bill Hearl, Ph.D., President & CEO240-731-5232bhearl@immunomictherapeutics.com